Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular effects of Apremilast in synovial biopsies of psoriatic arthritis patients
2019-003887-39Phase 2Completed
- Sponsor
- Cliniques universitaires Saint-Luc
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apremilast in psoriatic arthritis (PsA), sponsored by Cliniques universitaires Saint-Luc. Primary endpoint: Global transcriptomic changes in synovium after 24 weeks of apremilast therapy. Started Sep 2020; status: completed.
02
Drugs
apremilast
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2019-003887-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003887-39.